Videos

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

The director of pediatric epilepsy at HMN Hackensack University Medical Center provided background on how his data may change how clinicians use diazepam nasal spray.

The neurologist from Cleveland Clinic discussed the potential of using perampanel as a monotherapy for patients with focal onset seizures.

Episode 4 of the AUPN Leadership Minute features Clifton L. Gooch, MD, of the University of South Florida; and Robin Brey, MD, of the University of Texas Health Science Center at San Antonio. [WATCH TIME: 3 minutes]

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.

The director of pediatric epilepsy at the Northeast Regional Epilepsy Group discussed his study presented at AES 2020 which involved the effectiveness of diazepam nasal spray regardless of treatment regimen.

Neurology News Network for the week ending December 5, 2020.

The neurologist from Cleveland Clinic discussed initial data from Study 410 and patient compliance rates with perampanel treatment.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

The managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the process of determining the best situations for use of AMX0035.

The pediatric neurologist at Montefiore Health System provided her thoughts on the importance of Infantile Spasms Awareness Week.

The chief medical advisor for the Muscular Dystrophy Association discussed the organization’s recent annual telethon and the efforts to inform the public about these diseases.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the role insurance companies play within the system for approving neurological devices for rare diseases.

The research scientist from the University of Texas Medical School at Houston discussed the potential of machine learning to predict outcomes before symptoms arise.

The managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the potential of AMX0035 for the treatment of Alzheimer disease and other neurological diseases.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

Neurology News Network for the week ending November 28, 2020.

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

The managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the trial design and outcomes of the PEGASUS trial of AMX0035.

The chief scientific officer of the Parkinson’s Foundation offers his side of the debate on whether genetic testing for patients with Parkinson disease is under-utilized.

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed his experience using some of the approved medications for patients with Lennox-Gastaut syndrome.

The professor of neurology at the NYU Langone Grossman School of Medicine detailed the ways the COVID-19 pandemic impacted mental health of frontline clinicians.